“Daewoong Pharmaceutical received high praise for introducing the key research results and potential of the reflux disease treatment ‘Fexuclue’ to global digestive disease experts. Daewoong Pharmaceutical revealed that it promoted the research results of the reflux disease treatment ‘Fexuclue’ by operating a Fexuclue academic booth and holding a Fexuclue Reception Night symposium during the ‘2024 Digestive Disease Week (DDW)’ held in Washington D.C., USA from the 18th to the 4th (local time) for 4 days.
DDW, the world’s largest international digestive disease conference attended by doctors, researchers, industry officials, and others, was held with over 13,000 participants. Participating in DDW for the second consecutive year since last year, Daewoong Pharmaceutical showcased the latest insights and key research results of Fexuclue at the promotional booth from the 18th to the 21st.
At the Fexuclue booth, Daewoong Pharmaceutical introduced a total of 12 research projects, including 3 investigator-initiated basic research studies on anti-inflammatory effects, and additional analysis results of a phase 3 clinical trial targeting patients with mild erosive esophagitis in China presented as a poster.
On the 19th afternoon, the ‘Fexuclue Reception Night’ symposium was successfully held at the Marriott Hotel in Washington D.C. The event was attended by 100 doctors from 8 countries including Brazil, Colombia, Mexico, and Korea, with Professor Jeong Hoon-yong of Asan Medical Center and Professor Max Schmulson of the National Autonomous University of Mexico (UNAM) serving as co-chairs. Lectures on the proven efficacy of Fexuclue through various clinical trials, the superior effect of P-CAB class therapy compared to PPI class therapies, and case study presentations were delivered during the symposium.
Park Eun-kyung, the head of ETC marketing at Daewoong Pharmaceutical, stated, ‘This DDW booth and symposium served as a platform for global digestive disease experts to learn about Fexuclue and exchange various clinical results and treatment cases,’ and added, ‘We will continue to make efforts to establish Fexuclue as an effective option for treating reflux disease on the global treatment scene.’
Source: Naver News
Image: A Fexuclue academic booth set up at the ‘2024 Digestive Disease Week’. <Daewoong Pharmaceutical>“